《實驗與臨床癌癥研究雜志》尋求包括基礎(chǔ)癌癥研究重大進(jìn)展的手稿，并提供從實驗室到診所的轉(zhuǎn)化橋梁，為理解、預(yù)防、診斷和治療癌癥開辟新途徑。具體的關(guān)注領(lǐng)域包括但不限于：惡性表型和轉(zhuǎn)移性疾病的進(jìn)展機制；預(yù)測對治療的反應(yīng)或抗藥性的分子改變或生物標(biāo)志物；目標(biāo)療法中的翻譯研究；個性化醫(yī)學(xué)；生物信息學(xué)和生物統(tǒng)計學(xué)的新應(yīng)用；腫瘤免疫治療；人類腫瘤的大規(guī)模分子表征和具有臨床應(yīng)用潛力的創(chuàng)新方法。以下標(biāo)準(zhǔn)概述了該期刊所考慮的研究類型：該研究發(fā)現(xiàn)，以前沒有在同一個腫瘤模型中發(fā)表過。在多個細(xì)胞系中進(jìn)行的研究。這些結(jié)論并不代表漸進(jìn)的研究結(jié)果。研究包括明確的標(biāo)題和摘要，向非專家傳達(dá)研究的重要性。《實驗與臨床癌癥研究雜志》的在線出現(xiàn)使人們能夠立即發(fā)表可接受的文章，并提供大量數(shù)據(jù)和補充信息，以確保新的研究盡可能高效和迅速地傳播到科學(xué)界。

Journal of Experimental & Clinical Cancer Research seeks manuscripts that include significant advances in basic cancer research and that offer a translational bridge from the laboratory to the clinic to open new avenues for the understanding, prevention, diagnosis and treatment of cancer.Specific areas of interest include, but are not limited to: mechanisms of progression of the malignant phenotype and metastatic disease; molecular alterations or biomarkers that predict response or resistance to treatment; translational research in targeted therapies; personalized medicine; novel applications of bioinformatics and biostatistics; tumor immunotherapy; large-scale molecular characterization of human tumors and innovative methods with potential applicability to clinical investigation.The following criteria provide an overview of the types of studies considered by the journal:Findings that have not been previously published in the same tumor model.Studies performed in multiple cell lines.Conclusions that are not representative of incremental findings.Studies that include a clearly written title and abstract that communicate the study's impact of significance to non-experts.The online appearance of Journal of Experimental & Clinical Cancer Research allows the immediate publication of accepted articles and the presentation of large amounts of data and supplemental information to ensure that new research is disseminated as efficiently and quickly as possible to the scientific community.